
zzso zzso zzso the most frequent brain tumor in adults, is not considered zzso Nevertheless, there is widespread use of zzso chemotherapy, often with zzso as a therapeutic option in patients with progressive disease after surgery and zzso However, at the time of second recurrence and/or zzso active and zzso chemotherapy regimens are zzso The aim of the present zzso phase II trial, therefore, was to ascertain the efficacy of zzso zzso zzso and zzso zzso 

Patients with zzso confirmed zzso recurring or progressing after surgery, standard zzso and a zzso zzso chemotherapy, were considered zzso The primary zzso was zzso survival at 6 months zzso and secondary zzso included response rate, zzso and zzso All patients were on zzso zzso zzso zzso consisted of zzso zzso zzso on day 1) plus zzso zzso zzso for 4 weeks), every 6 weeks, for a maximum of eight zzso In the absence of grade 2 zzso the zzso dose was increased to 200 zzso 

A total of 42 patients zzso age, zzso years; median zzso performance status, zzso range, 60 to zzso were included in the zzso zzso was zzso zzso zzso zzso to zzso Median time to progression was 17 weeks zzso zzso zzso to zzso Nine partial responses zzso zzso zzso zzso to zzso were zzso zzso was zzso 

The zzso plus zzso regimen seems active and zzso in patients with zzso with recurrence after zzso zzso 

